New Risk • Apr 22
New major risk - Financial position The company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 1.0% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (1.0% operating cash flow to total debt). Minor Risks Paying a dividend despite having no free cash flows. Large one-off items impacting financial results. Announcement • Apr 13
Nanjing Pharmaceutical Group Company Limited, Annual General Meeting, May 08, 2026 Nanjing Pharmaceutical Group Company Limited, Annual General Meeting, May 08, 2026, at 14:00 China Standard Time. Location: 8F, Building 2, No. 55, Andemen Avenue, Yuhuatai District, Nanjing, Jiangsu China New Risk • Apr 11
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 30% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Large one-off items impacting financial results. Reported Earnings • Apr 11
Full year 2025 earnings released: EPS: CN¥0.48 (vs CN¥0.44 in FY 2024) Full year 2025 results: EPS: CN¥0.48 (up from CN¥0.44 in FY 2024). Revenue: CN¥55.0b (up 2.4% from FY 2024). Net income: CN¥624.8m (up 9.5% from FY 2024). Profit margin: 1.1% (in line with FY 2024). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings. Announcement • Mar 30
Nanjing Pharmaceutical Group Company Limited to Report Q1, 2026 Results on Apr 30, 2026 Nanjing Pharmaceutical Group Company Limited announced that they will report Q1, 2026 results on Apr 30, 2026 Announcement • Feb 28
Guangzhou GP Fund II Equity Investment Partnership completed the acquisition of 11.04% stake in NanJing Pharmaceutical Company Limited (SHSE:600713) from Alliance Healthcare Asia Pacific Limited. Guangzhou GP Fund II Equity Investment Partnership entered into a Share Transfer Agreement to acquire 11.04% stake in NanJing Pharmaceutical Company Limited (SHSE:600713) from Alliance Healthcare Asia Pacific Limited for approximately CNY 750 million on September 26, 2025. Guangzhou GP Fund II acquired 144,557,431 shares of Nanjing Pharmaceutical. A cash consideration valued at CNY 5.18 per share will be paid by Guangzhou GP Fund II Equity Investment Partnership. As part of consideration, an undisclosed value is paid towards common equity of NanJing Pharmaceutical Company Limited.
The Share Transfer Agreement involving GP Fund II, Alliance Healthcare Asia Pacific Limited, and Nanjing Pharmaceutical is subject to specific conditions precedent to closing. For Alliance Healthcare Asia Pacific Limited, the conditions include the proper formation and effect of the Share Transfer Agreement, GP Fund II obtaining all necessary internal and regulatory approvals, approval from the Shanghai Stock Exchange, the accuracy of GP Fund II's representations and warranties, completion of specified actions including tax documentation, and the absence of any legal impediments to the share transfer. Alliance Healthcare Asia Pacific Limited can waive certain conditions, except those related to the agreement's formation, regulatory approvals, and legal impediments. For GP Fund II, the conditions include the agreement's formation, the accuracy of Alliance Healthcare Asia Pacific Limited's representations and warranties, absence of legal impediments, Alliance Healthcare Asia Pacific Limited's internal approvals, and satisfactory due diligence results on Nanjing Pharmaceutical. GP Fund II can waive certain conditions, except those related to the agreement's formation, legal impediments, and Alliance Healthcare Asia Pacific Limited's internal approvals. Both parties retain the right to seek remedies for any waived conditions.
Guangzhou GP Fund II Equity Investment Partnership completed the acquisition of 11.04% stake in NanJing Pharmaceutical Company Limited (SHSE:600713) from Alliance Healthcare Asia Pacific Limited on February 26, 2026. Announcement • Dec 26
Nanjing Pharmaceutical Group Company Limited to Report Fiscal Year 2025 Results on Apr 11, 2026 Nanjing Pharmaceutical Group Company Limited announced that they will report fiscal year 2025 results on Apr 11, 2026 Reported Earnings • Oct 31
Third quarter 2025 earnings released: EPS: CN¥0.087 (vs CN¥0.10 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.087 (down from CN¥0.10 in 3Q 2024). Revenue: CN¥13.2b (down 3.9% from 3Q 2024). Net income: CN¥110.7m (down 15% from 3Q 2024). Profit margin: 0.8% (down from 1.0% in 3Q 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 6% per year whereas the company’s share price has fallen by 2% per year. Announcement • Sep 30
NanJing Pharmaceutical Company Limited to Report Q3, 2025 Results on Oct 31, 2025 NanJing Pharmaceutical Company Limited announced that they will report Q3, 2025 results on Oct 31, 2025 New Risk • Sep 07
New major risk - Financial position The company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 5.7% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (5.7% operating cash flow to total debt). Minor Risk Dividend is not well covered by cash flows (159% cash payout ratio). Announcement • Jun 30
NanJing Pharmaceutical Company Limited to Report First Half, 2025 Results on Aug 30, 2025 NanJing Pharmaceutical Company Limited announced that they will report first half, 2025 results on Aug 30, 2025 Announcement • May 09
NanJing Pharmaceutical Company Limited, Annual General Meeting, Jun 05, 2025 NanJing Pharmaceutical Company Limited, Annual General Meeting, Jun 05, 2025, at 14:00 China Standard Time. Location: 8F, Building 2, No. 55, Andemen Avenue, Yuhuatai District, Nanjing, Jiangsu China Reported Earnings • Apr 11
Full year 2024 earnings released: EPS: CN¥0.44 (vs CN¥0.45 in FY 2023) Full year 2024 results: EPS: CN¥0.44 (down from CN¥0.45 in FY 2023). Revenue: CN¥53.7b (flat on FY 2023). Net income: CN¥570.6m (down 1.2% from FY 2023). Profit margin: 1.1% (in line with FY 2023). Over the last 3 years on average, earnings per share has fallen by 6% per year whereas the company’s share price has fallen by 3% per year. Announcement • Mar 28
NanJing Pharmaceutical Company Limited to Report Q1, 2025 Results on Apr 30, 2025 NanJing Pharmaceutical Company Limited announced that they will report Q1, 2025 results on Apr 30, 2025 Announcement • Mar 17
NanJing Pharmaceutical Company Limited (SHSE:600713) announces an Equity Buyback for CNY 131.58 million worth of its shares. NanJing Pharmaceutical Company Limited (SHSE:600713) announces a share repurchase program. Under the program, the company will repurchase up to CNY 131.58 million worth of its shares. The shares will be repurchased at a price of CNY 7.31 per share. The program will be financed via own funs or self-generated funds. The purpose of the program is to use for ESOP or equity incentives. The repurchased shares will be used to implement the company's 2025 restricted stock incentive plan and un transferred shares will be cancelled. The repurchase program is valid for 12 months. Announcement • Dec 27
NanJing Pharmaceutical Company Limited to Report Fiscal Year 2024 Results on Apr 10, 2025 NanJing Pharmaceutical Company Limited announced that they will report fiscal year 2024 results on Apr 10, 2025 New Risk • Nov 10
New major risk - Financial position The company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 15% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. This is currently the only risk that has been identified for the company. Reported Earnings • Oct 31
Third quarter 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.10 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.10 (down from CN¥0.10 in 3Q 2023). Revenue: CN¥13.7b (up 3.8% from 3Q 2023). Net income: CN¥130.6m (flat on 3Q 2023). Profit margin: 1.0% (in line with 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings. Announcement • Sep 30
NanJing Pharmaceutical Company Limited to Report Q3, 2024 Results on Oct 31, 2024 NanJing Pharmaceutical Company Limited announced that they will report Q3, 2024 results on Oct 31, 2024 Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to CN¥5.03, the stock trades at a trailing P/E ratio of 11.3x. Average trailing P/E is 32x in the Healthcare industry in China. Total returns to shareholders of 23% over the past three years. Reported Earnings • Sep 03
Second quarter 2024 earnings released: EPS: CN¥0.12 (vs CN¥0.12 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.12 (down from CN¥0.12 in 2Q 2023). Revenue: CN¥13.3b (flat on 2Q 2023). Net income: CN¥152.2m (down 4.5% from 2Q 2023). Profit margin: 1.1% (down from 1.2% in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has fallen by 3% per year. Announcement • Jun 28
NanJing Pharmaceutical Company Limited to Report First Half, 2024 Results on Aug 30, 2024 NanJing Pharmaceutical Company Limited announced that they will report first half, 2024 results on Aug 30, 2024 Announcement • Apr 08
NanJing Pharmaceutical Company Limited, Annual General Meeting, May 31, 2024 NanJing Pharmaceutical Company Limited, Annual General Meeting, May 31, 2024, at 09:00 China Standard Time. Location: 3F, Building A, No. 19, Ningshuang Road, Yuhuatai District, Nanjing, Jiangsu China Reported Earnings • Apr 08
Full year 2023 earnings released: EPS: CN¥0.45 (vs CN¥0.47 in FY 2022) Full year 2023 results: EPS: CN¥0.45 (down from CN¥0.47 in FY 2022). Revenue: CN¥53.6b (up 6.7% from FY 2022). Net income: CN¥577.8m (down 3.0% from FY 2022). Profit margin: 1.1% (down from 1.2% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 3% per year. Announcement • Mar 29
NanJing Pharmaceutical Company Limited to Report Q1, 2024 Results on Apr 30, 2024 NanJing Pharmaceutical Company Limited announced that they will report Q1, 2024 results on Apr 30, 2024 Announcement • Dec 29
NanJing Pharmaceutical Company Limited to Report Fiscal Year 2023 Results on Apr 08, 2024 NanJing Pharmaceutical Company Limited announced that they will report fiscal year 2023 results on Apr 08, 2024 Reported Earnings • Nov 01
Third quarter 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.11 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.10 (down from CN¥0.11 in 3Q 2022). Revenue: CN¥13.2b (down 2.2% from 3Q 2022). Net income: CN¥131.7m (down 3.9% from 3Q 2022). Profit margin: 1.0% (in line with 3Q 2022). Over the last 3 years on average, earnings per share has increased by 10% per year whereas the company’s share price has increased by 5% per year. Reported Earnings • Aug 31
Second quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.16 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.12 (down from CN¥0.16 in 2Q 2022). Revenue: CN¥13.3b (up 8.3% from 2Q 2022). Net income: CN¥159.5m (down 21% from 2Q 2022). Profit margin: 1.2% (down from 1.6% in 2Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Apr 27
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥5.95, the stock trades at a trailing P/E ratio of 13.1x. Average trailing P/E is 29x in the Healthcare industry in China. Total returns to shareholders of 46% over the past three years. Reported Earnings • Apr 01
Full year 2022 earnings released: EPS: CN¥0.47 (vs CN¥0.48 in FY 2021) Full year 2022 results: EPS: CN¥0.47. Revenue: CN¥50.2b (up 11% from FY 2021). Net income: CN¥595.7m (up 18% from FY 2021). Profit margin: 1.2% (up from 1.1% in FY 2021). The increase in margin was driven by higher revenue. Board Change • Nov 16
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 8 experienced directors. 1 highly experienced director. 3 independent directors (6 non-independent directors). Independent Director Wenming Li was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Oct 30
Third quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.12 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.11. Revenue: CN¥13.5b (up 17% from 3Q 2021). Net income: CN¥137.0m (up 11% from 3Q 2021). Profit margin: 1.0% (in line with 3Q 2021). Reported Earnings • Oct 30
Third quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.12 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.11. Revenue: CN¥13.5b (up 17% from 3Q 2021). Net income: CN¥137.0m (up 11% from 3Q 2021). Profit margin: 1.0% (in line with 3Q 2021). Reported Earnings • Aug 28
Second quarter 2022 earnings released: EPS: CN¥0.16 (vs CN¥0.12 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.16 (up from CN¥0.12 in 2Q 2021). Revenue: CN¥12.2b (up 13% from 2Q 2021). Net income: CN¥200.7m (up 67% from 2Q 2021). Profit margin: 1.6% (up from 1.1% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Reported Earnings • May 02
First quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.098 in 1Q 2021) First quarter 2022 results: EPS: CN¥0.11 (up from CN¥0.098 in 1Q 2021). Revenue: CN¥11.7b (up 5.6% from 1Q 2021). Net income: CN¥132.6m (up 30% from 1Q 2021). Profit margin: 1.1% (up from 0.9% in 1Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Board Change • Apr 27
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 9 experienced directors. 1 highly experienced director. 3 independent directors (6 non-independent directors). Independent Director Wenming Li was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Mar 28
Full year 2021 earnings released: EPS: CN¥0.48 (vs CN¥0.36 in FY 2020) Full year 2021 results: EPS: CN¥0.48 (up from CN¥0.36 in FY 2020). Revenue: CN¥45.1b (up 13% from FY 2020). Net income: CN¥505.2m (up 34% from FY 2020). Profit margin: 1.1% (up from 0.9% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Reported Earnings • Oct 31
Third quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.11 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥11.5b (up 6.5% from 3Q 2020). Net income: CN¥124.0m (up 13% from 3Q 2020). Profit margin: 1.1% (up from 1.0% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Announcement • Sep 11
NanJing Pharmaceutical Company Limited announced that it expects to receive CNY 999.999998 million in funding from Nanjing XinGong Investment Group Co., Ltd NanJing Pharmaceutical Company Limited announced that it has signed a share subscription agreement for a private placement of 251,256,281 shares at an issue price of CNY 3.98 per share for gross proceeds of not more than CNY 999,999,998 on September 10, 2021. The transaction will include participation from returning investor Nanjing XinGong Investment Group Co., Ltd. All securities issued in the transaction have a hold period of 36 months. The transaction has been approved in the 11th meeting of the 8th Board of Directors of the company and is still subject to approval from state-owned assets supervision and administration department, state-owned assets supervision and administration department and China Securities Regulatory Commission. Reported Earnings • Aug 22
Second quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.093 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥10.8b (up 14% from 2Q 2020). Net income: CN¥120.4m (up 25% from 2Q 2020). Profit margin: 1.1% (up from 1.0% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • May 29
Investor sentiment improved over the past week After last week's 21% share price gain to CN¥5.58, the stock trades at a trailing P/E ratio of 14.5x. Average trailing P/E is 25x in the Healthcare industry in China. Total returns to shareholders of 15% over the past three years. Reported Earnings • Apr 30
First quarter 2021 earnings released: EPS CN¥0.098 (vs CN¥0.073 in 1Q 2020) The company reported a solid first quarter result with improved earnings and revenues, although profit margins were flat. First quarter 2021 results: Revenue: CN¥11.1b (up 26% from 1Q 2020). Net income: CN¥102.0m (up 34% from 1Q 2020). Profit margin: 0.9% (in line with 1Q 2020). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 29
Full year 2020 earnings released: EPS CN¥0.36 (vs CN¥0.33 in FY 2019) The company reported a solid full year result with improved earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: CN¥39.8b (up 7.2% from FY 2019). Net income: CN¥376.4m (up 8.5% from FY 2019). Profit margin: 0.9% (in line with FY 2019). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Announcement • Mar 05
NanJing Pharmaceutical Company Limited to Report Fiscal Year 2020 Results on Mar 27, 2021 NanJing Pharmaceutical Company Limited announced that they will report fiscal year 2020 results on Mar 27, 2021 Is New 90 Day High Low • Feb 04
New 90-day low: CN¥4.06 The company is down 9.0% from its price of CN¥4.45 on 06 November 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 10.0% over the same period. Is New 90 Day High Low • Jan 11
New 90-day low: CN¥4.29 The company is down 9.0% from its price of CN¥4.71 on 13 October 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 12% over the same period. Reported Earnings • Oct 30
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥335.3m, down 6.8% from the prior year. Total revenue was CN¥38.5b over the last 12 months, up 7.8% from the prior year. Is New 90 Day High Low • Oct 27
New 90-day low: CN¥4.52 The company is down 7.0% from its price of CN¥4.86 on 29 July 2020. The Chinese market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 10.0% over the same period. Announcement • Jul 09
NanJing Pharmaceutical Company Limited to Report First Half, 2020 Results on Aug 22, 2020 NanJing Pharmaceutical Company Limited announced that they will report first half, 2020 results on Aug 22, 2020